Aaron Goodman, MD, discusses recent changes to the frontline treatment of patients with peripheral T-cell lymphoma and the challenges of targeting T-cell lymphoma.
R. Lor Randall, MD, FACS, discusses the SAFETY trial (NCT03944798) in soft tissue sarcoma.
The potential therapeutic benefits of immune checkpoint inhibitors as monotherapy as well as in combination with chemotherapy for patients with non–small cell lung cancer depend greatly on the timing of treatment initiation. However, for patients with EGFR, ALK, and other actionable mutations, identifying the optimal combination is a hurdle.
R. Lor Randall, MD, discusses the referral challenges for orthopedic oncologists and the importance of improving quality of life for patients with metastatic bone disease.
R. Lor Randall, MD, FACS, discusses ongoing research in sequencing the tumors of patients with primary bone or tissue sarcomas.
Karen Kelly, MD, discusses how to determine treatment after patients with lung cancer progress on TKIs.
R. Lor Randall, MD, FACS, discusses ongoing studies and treatment options in the orthopedic oncology landscape.
Jonathan Riess, MD, MS, discusses ongoing research with PARP inhibitors in lung cancer and potential biomarkers for this class of agents.